Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
Authors:
- Sharan MuraliSMSharan Murali
- Manikandanesan SakthivelMSManikandanesan Sakthivel
- Kamaraj PattabiKPKamaraj Pattabi
- Vettrichelvan VenkatasamyVVVettrichelvan Venkatasamy
- Jeromie Wesley Vivian ThangarajJTJeromie Wesley Vivian Thangaraj
- Anita SheteASAnita Shete
- Alby John VargheseAVAlby John Varghese
- Jaganathan ArjunJAJaganathan Arjun
- Chethrapilly Purushothaman Girish KumarCKChethrapilly Purushothaman Girish Kumar
- Pragya D YadavPragya D Yadav
- Rima SahayRSRima Sahay
- Triparna MajumdarTMTriparna Majumdar
Open Access
Abstract
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection statusClinical Microbiology and Infection, 2021
- SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021International Journal of Infectious Diseases, 2021
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsThe Lancet, 2021
- High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencingPLOS ONE, 2021
- SARS‐CoV‐2 re‐infection risk in AustriaEuropean Journal of Clinical Investigation, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Lessons learnt during the first 100 days of COVID-19 pandemic in IndiaIndian Journal of Medical Research, 2020
- Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in IndiaIndian Journal of Medical Research, 2020
- Open data kit2010